Troleandomycin
From Wikipedia, the free encyclopedia
 |
|
|
Troleandomycin
|
|
| Systematic (IUPAC) name | |
| [(3R,5S,6S,7R,8S,9R,12R,13S,14R,15R)-6-[(2S,3R,4S,6R)
-3-acetyloxy-4-dimethylamino-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S) -5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl -10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate |
|
| Identifiers | |
| CAS number | ? |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C41H67NO15 |
| Mol. mass | 813.968 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Troleandomycin is a macrolide antibiotic.
Side effects: It is a CYP3A (a type of cytochrome P450) inhibitor.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
